CD146 as a Prognostic-Related Biomarker in ccRCC Correlating With Immune Infiltrates

Lv, Zheng; Feng, Huayi; Wang, Tao; Li, Hongzhao; Zhang, Xu

doi:10.3389/fonc.2021.744107

Cited by 12 publications

(10 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NEK2, NIMA-related kinase 2, was found to be overexpressed in ccRCC and high expression of NEK2 was associated with a poor prognosis [ 56 ]. CD146 was identified to be elevated in ccRCC tissues, and high CD146 expression was associated with poor prognosis in patients with ccRCC [ 57 ]. FGL1, fibrinogen-like protein 1, which is known as a novel potential immune checkpoint target [ 58 ], was recognized to be upregulated in tumor tissues and plasma specimens of ccRCC patients, and high FGL1 expression predicted a poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Identification of IL20RB as a Novel Prognostic and Therapeutic Biomarker in Clear Cell Renal Cell Carcinoma

et al. 2022

View full text Add to dashboard Cite

Background. Clear cell renal cell carcinoma (ccRCC) is a type of life-threatening malignant tumor of the urinary system. IL20RB, interleukin 20 receptor subunit beta, is a cytokine receptor subunit coding gene and was initially found to play a vital role in human cancers, while its role in ccRCC still remains unclear. Methods. In this work, we explored the prognostic value and therapeutic potential of IL20RB in ccRCC mainly by online tools. Firstly, we used UALCAN and GEPIA to explore the expression profile and prognostic value of IL20RB in various cancers; the expression profile in tumor cell lines was also analysed with CCLE and Expression Atlas. Then, we decided to focus on ccRCC for further analysis; we further demonstrated the significant correlation between expression and clinical features by GEPIA and UALCAN. In order to reveal the potential intrinsic mechanism responsible for the upregulation of IL20RB in ccRCC, we made genetic alternation analysis and methylation analysis. cBioPortal was used for genetic alternation analysis. UALCAN, MethSurv, and Xena were used for methylation analysis. To learn details of how IL20RB might function in ccRCC, we further conducted functional analysis and immune infiltration analysis. STRING and GSEA were used to do functional analysis. TIMER was used for immune infiltration analysis; KM plotter was used for survival analysis. Results. Results show that IL20RB is upregulated in ccRCC, and low methylation may be responsible for its upregulation. Both high expression and low methylation of IL20RB predict worse survival, and both have a strong positive correlation with clinical characteristics. In addition, results indicate that there exists a crosstalk between IL20RB and neutrophils. Furthermore, the immune microenvironment could influence the prognosis predicting ability of IL20RB. Conclusions. In conclusion, IL20RB plays an important role in ccRCC and is identified as a novel prognostic and potential therapeutic biomarker in ccRCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of IL20RB as a Novel Prognostic and Therapeutic Biomarker in Clear Cell Renal Cell Carcinoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In view of the insensitivity of renal clear cell carcinoma to radiotherapy and chemotherapy, surgical operation is still the dominant treatment method, although the postoperative recurrence rate is still nearly 40%. In recent years, immunotherapy-based combinations have become the standard of treatment for patients with metastatic RCC and have shown effectiveness and improved overall survival in the first-line metastatic scenario ( Lv et al, 2021 ). As a heterogeneous disease, ccRCC still lacks effective biomarkers for individualized treatment methods, especially in current immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

High GTSE1 expression promotes cell proliferation, metastasis and cisplatin resistance in ccRCC and is associated with immune infiltrates and poor prognosis

Lei

Zhang

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Background: Clear cell renal cell carcinoma is the most common and fatal form of kidney cancer, accounting for 80% of new cases. Although it has been reported that GTSE1 is highly expressed in a variety of tumors and associated with malignant progression and poor clinical prognosis, its clinical significance, correlations with immune cell infiltration and biological function in ccRCC are still poorly understood.Methods: The gene expression, clinicopathological features, and clinical significance of GTSE1 were analyzed using multiple databases, including TCGA, GEO, TIMER, and UALCAN Kaplan–Meier survival analysis, gene set enrichment analysis gene ontology enrichment Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed. Tumor-infiltrating immune cells and immunomodulators were extracted and analyzed using TCGA-KIRC profiles. Protein‒protein interactions were built using the STRING website. The protein level of GTSE1 in ccRCC patients was detected by immunohistochemistry using a ccRCC tissue chip. Finally, MTT assays, colony-formation assays, cell flow cytometry analyses, EdU-staining assays, wound-healing assays, and transwell migration and invasion assays were conducted to assess the biological function of GTSE1 in vitro.Results: GTSE1 was overexpressed in ccRCC tissues and cells, and GTSE1 overexpression was associated with adverse clinical-pathological factors and poor clinical prognosis. Meanwhile, the functional enrichment analysis indicated that GTSE1 and its coexpressed genes were mainly related to the cell cycle, DNA replication, and immunoreaction, such as T-cell activation and innate immune response, through multiple signaling pathways, including the P53 signaling pathway and T-cell receptor signaling pathway. Furthermore, we observed a significant relationship between GTSE1 expression and the levels of infiltrating immune cells in ccRCC. Biological functional studies demonstrated that GTSE1 could promote the malignant progression of ccRCC by promoting cell proliferation, cell cycle transition, migration, and invasion capacity and decreasing the sensitivity of ccRCC cells to cisplatin.Conclusion: Our results indicate that GTSE1, serving as a potential oncogene, can promote malignant progression and cisplatin resistance in ccRCC. Additionally, high GTSE1 expression contributes to an increased level of immune cell infiltration and is associated with a worse prognosis, providing a potential target for tumor therapy in ccRCC.

show abstract

“…Moreover, TAM can promote tumor proliferation, angiogenesis, and metastasis ( 35 ). Recent research has demonstrated that an inflammatory environment can promote the occurrence and development of tumors ( 21 ). Therefore, we speculated that AQP5 expression promoted the generation and accelerated PAAD progression.…”

Section: Discussionmentioning

confidence: 99%

“…The normal pancreatic tissues of PAAD patients were obtained from Xijing Hospital. Western blotting, RT-PCR, immunofluorescence, and immunohistochemistry were performed as previously reported ( 21 – 23 ). The following antibodies were used: AQP5 (Abcam, Ab92320) and tubulin (Proteintech, 10094-1-AP).…”

Section: Methodsmentioning

confidence: 99%

AQP5 Is a Novel Prognostic Biomarker in Pancreatic Adenocarcinoma

et al. 2022

View full text Add to dashboard Cite

BackgroundPancreatic adenocarcinoma (PAAD) is a highly malignant tumor with a poor prognosis. The identification of effective molecular markers is of great significance for diagnosis and treatment. Aquaporins (AQPs) are a family of water channel proteins that exhibit several properties and play regulatory roles in human carcinogenesis. However, the association between Aquaporin-5 (AQP5) expression and prognosis and tumor-infiltrating lymphocytes in PAAD has not been reported.MethodsAQP5 mRNA expression, methylation, and protein expression data in PAAD were analyzed using GEPIA, UALCAN, HAP, METHSURV, and UCSC databases. AQP5 expression in PAAD patients and cell lines from our cohort was examined using immunohistochemistry and Western blotting. The LinkedOmics database was used to study signaling pathways related to AQP5 expression. TIMER and TISIDB were used to analyze correlations among AQP5, tumor-infiltrating immune cells, and immunomodulators. Survival was analyzed using TCGA and Kaplan–Meier Plotter databases.ResultsIn this study, we investigated AQP5 expression in PAAD and determined whether the expression of AQP5 is a strong prognostic biomarker for PAAD. We searched and analyzed public cancer databases (GEO, TCGA, HAP, UALCAN, GEPIA, etc.) to conclude that AQP5 expression levels were upregulated in PAAD. Kaplan–Meier curve analysis showed that high AQP5 expression positively correlated with poor prognosis. Using TIMER and TISIDB, we found that the expression of AQP5 was associated with different tumor-infiltrating immune cells, especially macrophages. We found that hypomethylation of the AQP5 promoter region was responsible for its high expression in PAAD.ConclusionsAQP5 can serve as a novel biomarker to predict prognosis and immune infiltration in PAAD.

show abstract

CD146 as a Prognostic-Related Biomarker in ccRCC Correlating With Immune Infiltrates

Cited by 12 publications

References 65 publications

Identification of IL20RB as a Novel Prognostic and Therapeutic Biomarker in Clear Cell Renal Cell Carcinoma

Identification of IL20RB as a Novel Prognostic and Therapeutic Biomarker in Clear Cell Renal Cell Carcinoma

High GTSE1 expression promotes cell proliferation, metastasis and cisplatin resistance in ccRCC and is associated with immune infiltrates and poor prognosis

AQP5 Is a Novel Prognostic Biomarker in Pancreatic Adenocarcinoma

Contact Info

Product

Resources

About